Skip to main content

Table 3 Survival outcome and length of stay

From: Continuation of chronic antiplatelet therapy is not associated with increased need for transfusions: a cohort study in critically ill septic patients

 

All patients

Matched patients

Variable

N

Discontinued,

N = 89

Continued,

N = 114

p-value1

N

Discontinued,

N = 60

Continued,

N = 60

p-value1

Survival

        

90-day survival, n (%)

203

34 (38.2%)

76 (66.7%)

< 0.001

120

18 (30.0%)

42 (70.0%)

< 0.001

ICU survival, n (%)

203

52 (58.4%)

91 (79.8%)

0.001

120

35 (58.3%)

48 (80.0%)

0.017

Hospital survival, n (%)

203

43 (48.3%)

85 (74.6%)

< 0.001

120

27 (45.0%)

45 (75.0%)

0.001

Length of stay

        

All patients

        

Hospital stay before sepsis onset [days], median (IQR)

203

2 (0, 10)

2 (0, 6)

0.91

120

3 (0, 9)

1 (0, 7)

0.84

ICU stay after sepsis onset [days], median (IQR)

203

6 (2, 14)

12 (6, 24)

< 0.001

120

6 (2, 14)

12 (6, 23)

0.002

Hospital stay [days], median (IQR)

203

21 (7, 49)

29 (17, 55)

0.012

120

21 (4, 46)

29 (15, 52)

0.046

Survivors of hospital stay

        

Hospital stay before sepsis onset [days], median (IQR)

128

2 (0, 9)

2 (0, 6)

0.85

72

4 (0, 9)

1 (0, 8)

0.64

ICU stay after sepsis onset [days], median (IQR)

128

8 (4, 16)

14 (7, 24)

0.019

72

8 (5, 16)

13 (7, 22)

0.092

Hospital stay [days], median (IQR)

128

28 (18, 50)

32 (20, 56)

0.47

72

28 (16, 46)

30 (20, 52)

0.50

  1. IQR: interquartile range; 1Fisher’s exact test; Wilcoxon rank sum test; Wilcoxon rank sum exact test